参考文献
1.NCCN Clinical Practice Guidelines in Oncology（NCCN Guidelines）: Central Nervous System Cancers Version 1.2019 — March 5, 2019.
2.American Joint Committee on Cancer（AJCC）Cancer Staging System（8th ed., 2017）.
3.Cabrera AR, Kirkpatrick JP, Fiveash JB, et al.Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.Pract Radiat Oncol 2016, 6: 217-225.
4.Roa W, Kepka L, Kumar N, et al.International Atomic Energy Agency randomized phase IIIstudy of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme.J Clin Oncol 2015, 33: 4145-4150.
5.Lee SH.Long-term outcomes of surgicalresection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group.Neuro Oncol 2013, 15: 921-929.
6.Brown AP, Barney CL, Grosshans DR.Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.Int J Radiat Oncol Biol Phys 2013, 86: 277-284.
7.Kasenda B, Loeffer J, IIIerhaus G, et al.The role of whole brain radiation in primary CNS lymphoma.Blood 2016, 1: 32-36.
8.Gondi V, Pugh S, Brown PD, et al.NCOG-01.Preservation of neurocognitive function（NCF）with hippocampal avoidance during whole-brain radiotherapy（WBRT）for brain metastases: preliminary results of phase III trail NRG Oncology CC001.Neuro Oncol 2018, 20: vi: 172-vi: 172.
9.Yamamoto M, Serizawa T, Shuto T, et al.Stereotactic radiosurgery for patients withmultiple brain metastases（JLGK0901）: amulti-institutional prospective observational study.Lancet Oncol 2014, 15: 387-395.
10.Brown PD, Ballman KV, Cerhan JH, et al.Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease（NCCTG N107C/CEC.3）: a multicentre, randomised, controlled, phase 3 trial.Lancet Oncol 2017, 18: 1049-1060.
11.Soliman H, Ruschin M, Angelov L, et al.Consensus Contouring Guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases.Int J Radiat Oncol Biol Phys 2018, 100: 436-442.
12.Redmond KJ, Lo SS, Soltys SG, et al.Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey.J Neurosurg Spine 2017, 26: 299-306.(https://www.daowen.com)
13.Redmond KJ, Robertson S, Lo SS, et al.Consensus contouring guidelines for postoperative stereotactic body radiation therapy for metastatic solid tumor malignancies to the spine.Int J Radiat Oncol BiolPhys 2017, 97: 64-74.
14.Buckner JC, Shaw EG, Pugh SL, et al.Radiation plus procarbazine, CCNU, and vincristine in lowgrade glioma.N Engl J Med 2016, 374: 1344-1355.
15.Shaw EG, Wang M, Coons SW, et al.Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult lowgrade glioma: initial results of RTOG 9802.J ClinOncol 2012, 30: 3065-3070.
16.Fisher BJ, Hu C, Macdonald DR, et al.Phase 2 study of temozolomide-based chemoradiation therapy for highrisk low-grade gliomas: preliminaryresultsofRadiationTh erapyOncology Group 0424.Int J Radiat Oncol BiolPhys 2015, 91: 497-504.
17.Franz DN, Belousova E, Sparagana S, et al.Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex（EXIST-1）: a multicentre, randomised, placebocontrolled phase 3 trial.Lancet 2013, 381: 125-132.
18.van den Bent MJ, Brandes AA, Taphoorn MJ, et al.Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.J Clin Oncol 2013, 31: 344-350.
19.Jaeckle K, Vogelbaum M, Ballman K, et al.CODEL（Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2）: phase III randomized study of RT vs.RT+TMZ vs.TMZ for newly diagnosed 1p/19q-codeleted anaplastic oligodendroglial tumors.Neurology 2016, 86.
20.Panageas KS, Iwamoto FM, Cloughesy TF, et al.Initial treatment patterns over time for anaplastic oligodendroglial tumors.Neuro Oncol 2012, 14: 761-767.
21.van den Bent MJ, Baumert B, Erridge SC, et al.Interim results from the CATNON trial（EORTC study 26053-22054）of treatment with concurrent and adjuvant temozolomide for1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.Lancet 2017, 390: 1645-1653.
22.Vaccaro V, Fabi A, Vidiri A, et al.Activityand safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Biomed Res Int 2014, 2014: 351252.
23.Liu Y, Feng F, Ji P, et al.Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.Clin Neurol Neurosurg 2018, 169: 64-70.
24.van den Bent MJ, Klein M, Smits M, et al.Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion（TAVAREC）: a randomized controlled phase 2 EORTC trial.Lancet Oncol 2018, 19: 1170-1179.